Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Luveris reaches first market following late November approval by European Commission

June 1, 2001

Improvement in glucose tolerance and insulin secretion produced by Shionogi compounds

May 30, 2001

MCH antagonists and their utility described by Takeda

May 30, 2001

Locally active estrogens useful for menopausal vaginal dyspareunia

May 30, 2001

FDA approves King's NDA for Levoxyl

May 29, 2001

Small molecule from Point Therapeutics stimulates hematopoiesis, advances in clinical testing

May 29, 2001

Squalene synthase inhibitors designed at Eisai inhibit cholesterol biosynthesis

May 28, 2001

New osteoclast vacuolar H+-ATPase inhibitors in the AstraZeneca portfolio

May 28, 2001

Bisphosphonic acid derivatives and use in treatment, diagnosis of bone diseases

May 28, 2001

Potentially orally active, potent steroidal androgens designed at Organon

May 28, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...